NCT05801783View on ClinicalTrials.gov

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 2, 2022

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2025

Conditions
Ovarian CancerPeritoneal CarcinomatosisFallopian Tube Cancer
Interventions
DRUG

Recombinant oncolytic herpes simplex virus type 1 (R130)

R130, a modified herpes simplex virus-1 (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11

Trial Locations (1)

200000

RECRUITING

Shanghai Tenth People's Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai 10th People's Hospital

OTHER

lead

Shanghai Yunying Medical Technology

INDUSTRY